Please ensure Javascript is enabled for purposes of website accessibility

Why Pacira Biosciences Stock Sank Today

By Keith Speights – Oct 4, 2021 at 3:56PM

Key Points

  • eVenus Pharmaceutical Laboratories has filed for FDA approval of a generic version of Pacira's Exparel.
  • The non-opioid pain drug generated nearly all of Pacira's revenue in the second quarter.
  • Pacira plans to "vigorously defend its intellectual property rights."

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A potential rival hopes to win FDA approval of a generic version of Pacira's top-selling pain drug.

What happened

Shares of Pacira BioSciences (PCRX -1.73%) were sinking 12.7% as of 3:33 p.m. EDT on Monday. The decline came after the company announced that eVenus Pharmaceutical Laboratories is seeking Food and Drug Administration approval for a generic version of non-opioid pain drug Exparel.

So what

The possibility of generic competition for Exparel presents a key challenge for Pacira. In the second quarter, the drug generated $130.1 million of the company's total $135.6 million in sales. It's not surprising, therefore, that the pharma stock took a big hit today.

A patient in a hospital bed with a healthcare professional at the bedside.

Image source: Getty Images.

But investors shouldn't put the cart before the horse here. So far, eVenus has only filed an Abbreviated New Drug Application (ANDA) with the FDA. The company is challenging the validity of Pacira's patent. But that patent represents only one of several pending patents that Pacira thinks could extend its marketing position for Exparel into the 2040s.

Now what

Pacira stated in a press release that it's "currently assessing" the notice letter it received related to eVenus' ANDA filing. The company has 45 days to initiate legal action against eVenus for patent infringement. It seems likely that's the course that Pacira will take, considering the company's statement that it "intends to vigorously defend its intellectual property rights relating to Exparel."

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.